Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
185
resultados
Última actualización
07/12/2025 [07:47:00]
Resultados 50 a 75 de 185
Resumen de: WO2025186390A1
The present invention refers to an in vitro method for predicting the response of a patient suffering from ulcerative colitis to a treatment with anti-tumor necrosis factor (TNF) antibodies.
Resumen de: CN120617562A
The invention belongs to the technical field of biological medicine, and particularly relates to a preparation method of a magnetic resonance/fluorescence bimodal nanometer diagnosis and treatment agent based on nitrogen oxide. The preparation method comprises the following steps: firstly, respectively modifying distearoyl phosphatidyl ethanolamine phospholipid and IR780 by utilizing TEMPO to prepare DSPE-PEG-TEMPO and an ROS responsive fluorescent probe IT, then embedding the phospholipid into a macrophage cell membrane by utilizing cell membrane fluidity, and wrapping the fluorescent probe IT and curcumin in an ultrasonic and extrusion manner, so as to prepare the bionic nano diagnosis and treatment agent based on MRI/FL dual-mode imaging. Wherein the TEMPO not only has MRI (Magnetic Resonance Imaging) performance, but also can remove active oxygen; the ROS response type fluorescent probe can track the focus of the inflammatory bowel disease through fluorescence imaging and is used for surgical navigation; the anti-inflammatory drug curcumin can be slowly released at the focus part. Through the synergistic effect of the three components and the inflammation tendency of the macrophage membrane, accurate imaging and drug release treatment of the inflammatory bowel disease are expected to be realized.
Resumen de: CN120617394A
The invention relates to the technical field of traditional Chinese medicines, in particular to application of a qi-stagnation stomachache preparation in preparation of a medicine for treating irritable bowel syndrome. According to the application of the qi-stagnation stomachache preparation in preparation of the medicine for treating the irritable bowel syndrome, the diarrhea condition of the diarrhea type irritable bowel syndrome can be improved, meanwhile, anxiety and visceral hypersensitivity caused by the irritable bowel syndrome can be relieved, and therefore the preparation can be used for preparing the medicine for treating the qi-stagnation stomachache. The qi stagnation and stomachache preparation has a remarkable improvement effect on diarrhea type irritable bowel syndrome (IBS-D).
Resumen de: WO2025185637A1
Provided are methods for determining the risk of, diagnosing, preventing, or treating Crohn's Disease (CD), ulcerative colitis (UC) and/or inflammatory bowel disease (IBD) in an individual. Some embodiments provide kits and computer program products for determining the risk of or diagnosing Crohn's Disease (CD), ulcerative colitis (UC) and/or inflammatory bowel disease (IBD) in an individual. Other example embodiments are described herein. In certain embodiments, the disclosed methods and kits are accurate, cost-effective and non-invasive.
Resumen de: WO2025185773A1
Disclosed in the present invention are an antibody targeting TL1A and the use thereof. The antibody of the present invention can be used for blocking the interaction between TL1A and DR3, is helpful for achieving the purpose of intervention from the early stages of inflammation, inhibits immune cells such as effector T cells to release cytokines for promoting an inflammatory response, and provides more possibilities for treatment methods for IBD patients or other TL1A-related diseases.
Resumen de: WO2025188870A1
Provided herein are methods of identifying a subject as having an inflammatory bowel disorder, wherein a method includes (a) determining a level of NXPE1 in a biological sample from the subject; and (b) comparing the level of NXPE1 in the biological sample to a reference level, wherein the presence of a level of NXPE1 in the biological sample above the reference level indicates that the subject has an inflammatory bowel disorder.
Resumen de: US2025281553A1
Described herein are bacteriophages that infect and lyse adherent-invasive Escherichia coli (AIEC). The bacteriophages are useful, for example, for the prophylactic or therapeutic treatment of subjects infected with AIEC or at risk of infection by AIEC, or in the prophylactic or therapeutic treatment of diseases and conditions associated with AIEC, including inflammatory bowel disease (IBD), urinary tract infection (UTI), neonatal meningitis, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, pneumonia, and lung cancer, in a subject in and for other uses described herein.
Resumen de: EP4614151A1
The present invention refers to an in vitro method for predicting the response of a patient suffering from ulcerative colitis to a treatment with anti-tumor necrosis factor (TNF) antibodies.
Resumen de: WO2024094817A1
The present invention relates to a score (TOPOSCORE) for describing eubiosis or dysbiosis in an individual, that can be used, inter alia, for determining if a patient is likely to respond to an immune-oncology treatment, more precisely, a treatment comprising administration of an immune checkpoint inhibitor (ICI). The TOPOSCORE represents a robust biomarker predicting immunosensitivity and immunoresistance to ICI on an individual basis.
Resumen de: CN120605330A
The invention discloses a novel application of a transient receptor potential cation channel subgroup C member 4 (TRPC4) inhibitor in preparation of a medicine for preventing or treating inflammatory bowel disease (IBD). The research finds that in a colitis mouse model, the enteritis symptom of the colitis mouse can be obviously improved by systemic gene knockout of TRPC4 or application of a TRPC4 inhibitor. Therefore, the TRPC4 is related to the disease progress of the colitis, and the TRPC4 can be used as a biomarker for screening patients and predicting the curative effect.
Resumen de: AU2023327783A1
Embodiments include a method for detecting small intestinal bacterial overgrowth, SIBO, the method comprising: obtaining data representing a time series of readings from gas sensor hardware housed within an ingestible capsule device orally ingested by a subject, identifying the data corresponding to timing of passage through the small intestine, and determining whether or not the data indicates presence of SIBO.
Resumen de: CN120594728A
The invention discloses a method for determining the content of organic acid metabolites of dark plums in colon tissue and application. The determination method comprises the following steps: (1) adding sterilized normal saline into colon tissues, grinding, adding methanol, continuously grinding, centrifuging, taking a supernatant, adding methanol for vortex, centrifuging, and finally adding water for vortex to obtain a sample solution to be detected; (2) a high performance liquid chromatography-mass spectrometry method is adopted, citric acid, malic acid and quinic acid standard substances are used for drawing standard curves of the three organic acids, citric acid adopts a positive ion mode, and malic acid and quinic acid adopt a negative ion mode; and (3) detecting the sample to be detected by adopting the same method, and calculating the concentrations or contents of the three organic acid metabolites (citric acid, malic acid and quinic acid) according to the standard curve. The method is simple and high in sensitivity, and can be used for researching the mechanism of the smoked plum acting on the ulcerative colitis.
Resumen de: CN120590530A
The invention discloses a TL1A targeting antibody and an application thereof. The antibody provided by the invention can be used for blocking the interaction between TL1A and DR3, is helpful to achieve the purpose of intervention from the early stage of inflammation, inhibits immune cells such as effector T cells from releasing cytokines for proinflammatory reaction, and provides more possibilities for treatment methods of IBD patients or other TL1A related diseases.
Resumen de: US2025277269A1
This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.
Resumen de: WO2025181330A1
The present disclosure relates to dosage regimens for glucagon-like-peptide-2 (GLP-2) analogs, e.g., apraglutide, in a subject in need thereof, e.g., a subject with short bowel syndrome (SBS).
Resumen de: WO2025184435A1
The present invention provides an improved breath analyzer and breath test method to determine the presence of disease in humans, including but not limited to, H. pylori infection, Celiac Disease, Metabolic dysfunction-associated steatohepatitis (MAHD), Inflammatory Bowel Disease (JBD). 'm a subject's digestive tract. In certain embodiments, the present invention provides a universal breath testing platform and methods of testing for diseases of the gastrointestinal tract, the liver, the kidneys, and the lungs, along with testing for cancer, infections, and metabolic diseases.
Resumen de: WO2025181327A1
The present invention relates to a method for determining a need for adjustment of parenteral supplementation, risk of developing acid-base imbalance, and monitoring development of acid-base imbalance in a subject receiving parenteral supplementation and having intestinal insufficiency, such as short bowel. In particular, the present invention relates to determining urinary net acid excretion (NAE) for evaluating acid-base imbalances in subjects having intestinal insufficiency, such as short bowel, in order to determine risk of developing and/or monitoring development of acid-base imbalance, as well as adjustment of parenteral supplementation.
Resumen de: EP4610657A1
Provided are a method for detecting an immune-mediated inflammatory disease characterized by an increase in expression of MMP12, in a subject, a diagnostic drug containing a substance that specifically interacts with MMP12, and a therapeutic agent containing an MMP12 inhibitory substance.
Resumen de: US2025243548A1
Described herein are methods and compositions related to the discovery of associations in TNFSF15 15 and DcR3 genetic loci across in Caucasian, Puerto Rican, and Korean Crohn's Disease, as demonstrated via trans-ethnic fine mapping. The present invention provides methods of quantifying risk and diagnosing susceptibility to Crohn's disease in a subject by determining the presence of one or more risk variants are at the TNFSF15 (or TL1A) and/or DcR3 genetic loci.
Resumen de: CN120577530A
The invention discloses a therapeutic target for inflammatory bowel disease and application thereof. Research finds that NO can be combined with an enzyme active site of a CYP450 family member, so that the activity of the CYP450 family member is inhibited, finally generation of a pathogenic factor GM-CSF is inhibited, and enteritis is relieved. On the basis, an inflammatory bowel disease product, a kit and an analysis system are developed. According to the invention, a new strategy can be provided for preventing, detecting and treating intestinal inflammatory diseases, and the intestinal homeostasis imbalance can be effectively improved.
Resumen de: MX2025009868A
The present disclosure generally relates to methods, and diagnostic applications, for the treatment of ulcerative colitis. More particularly the methods and diagnostic applications of the present invention relate to expression profiles of certain gene transcripts in ulcerative colitis patients and the usefulness of the expression profiles of these gene transcripts for the treatment, and/or diagnostic use in a subgroup of patients having ulcerative colitis.
Resumen de: AU2024213250A1
The present disclosure provides compositions and methods for using stool-derived, eukaryotic, nucleic acid biomarkers to diagnose disease, assess disease activity, monitor mucosal healing, and predict therapeutic response. The described biomarkers can be used by practitioners to better diagnose, manage, and treat inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD).
Resumen de: CN120554525A
The invention provides a fusion protein as well as a preparation method and application thereof. Specifically, the fusion protein disclosed by the invention has a structure as shown in a formula I: in the formula, Z0 is a tag sequence for purposes of purification, separation and the like; z1 is a human serum amyloid A protein fragment; l1 is none or a joint; z2 is fluorescent protein. The invention provides a preparation method and application of the fusion protein, the method is high in yield and free of risks of cross infection, gene mutation and the like, and the Clover-SSA1 protein prepared through the method can be used in the research fields of disease diagnosis, drug screening, biomarkers and the like, namely Z0-Z1-L1-Z2 (I).
Resumen de: CN120550120A
The invention discloses an application of inhibiting CD4 + T cell aging in preparation of a medicine for slowing down the progress of elderly ulcerative colitis. The invention provides an application of a substance for inhibiting the aging of CD4 + T cells in preparation of a product with at least one of the following functions: preventing senile ulcerative colitis; treating the elderly ulcerative colitis; the progress of elderly ulcerative colitis is relieved; diseases caused by aging of CD4 + T cells can be prevented or treated. A mouse model of specific knockout of the CD4 + T cell METTL3 is constructed, and it is found that specific knockout of the CD4 + T cell METTL3 can significantly inhibit the aging phenotype of the CD4 + T cell, so that DSS-induced mouse colitis and T cell adoptive transfer mediated enteritis are relieved. By improving CD4 + T cell senescence, UC, especially the progress of elderly UC, is relieved.
Nº publicación: CN120549942A 29/08/2025
Solicitante:
NINGXIA UNIV
\u5B81\u590F\u5927\u5B66
Resumen de: CN120549942A
According to the application, the application of the taurocholic acid (TCA) in the medicine for preventing and treating the colitis injury is found and proved, the clinical effect is remarkable, the TCA with a proper concentration can promote the growth of Caco-2 cells and can relieve inflammation caused by LPS, but the TCA with a high concentration can inhibit the growth of the Caco-2 cells. Through intragastric administration of TCA, mouse colitis induced by escherichia coli can be relieved, TCA with a proper concentration can treat colitis, and through in-vitro and in-vivo dual verification, the optimal concentration of TCA in the aspect of treating colitis and the treatment effect of TCA on colitis caused by pathogenic escherichia coli are determined. Theoretical support is provided for medicine development of TCA in the aspect of treating intestinal inflammation, and the TCA is worthy of being widely popularized and used clinically.
BOPI
Sede Electrónica
